These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 9870147

  • 1. Loss of bcl-2 expression in ductal carcinoma in situ of the breast relates to poor histological differentiation and to expression of p53 and c-erbB-2 proteins.
    Quinn CM, Ostrowski JL, Harkins L, Rice AJ, Loney DP.
    Histopathology; 1998 Dec; 33(6):531-6. PubMed ID: 9870147
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin.
    Megha T, Ferrari F, Benvenuto A, Bellan C, Lalinga AV, Lazzi S, Bartolommei S, Cevenini G, Leoncini L, Tosi P.
    J Clin Pathol; 2002 Jun; 55(6):461-6. PubMed ID: 12037031
    [Abstract] [Full Text] [Related]

  • 4. Oestrogen receptor negativity as a marker for high-grade ductal carcinoma in situ of the breast.
    Baqai T, Shousha S.
    Histopathology; 2003 May; 42(5):440-7. PubMed ID: 12713620
    [Abstract] [Full Text] [Related]

  • 5. Immunohistochemical categorisation of ductal carcinoma in situ of the breast.
    Meijnen P, Peterse JL, Antonini N, Rutgers EJ, van de Vijver MJ.
    Br J Cancer; 2008 Jan 15; 98(1):137-42. PubMed ID: 18043578
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
    Mylonas I, Makovitzky J, Jeschke U, Briese V, Friese K, Gerber B.
    Anticancer Res; 2005 Jan 15; 25(3A):1719-23. PubMed ID: 16033090
    [Abstract] [Full Text] [Related]

  • 11. Biological profile of in situ breast cancer investigated by immunohistochemical technique.
    Albonico G, Querzoli P, Ferretti S, Rinaldi R, Nenci I.
    Cancer Detect Prev; 1998 Jan 15; 22(4):313-8. PubMed ID: 9674874
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Reciprocal expression of Bcl-2 and p53 in breast ductal carcinoma.
    Lee WY, Jin YT, Tzeng CC.
    Anticancer Res; 1996 Jan 15; 16(5A):3007-12. PubMed ID: 8917421
    [Abstract] [Full Text] [Related]

  • 17. Retinoic acid receptor and retinoid X receptor in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
    Ariga N, Moriya T, Suzuki T, Kimura M, Ohuchi N, Sasano H.
    Jpn J Cancer Res; 2000 Nov 15; 91(11):1169-76. PubMed ID: 11092983
    [Abstract] [Full Text] [Related]

  • 18. Multiple developmental pathways of highly aggressive breast cancers disclosed by comparison of histological grades and c-erbB-2 expression patterns in both the non-invasive and invasive portions.
    Tsuda H, Hirohashi S.
    Pathol Int; 1998 Jul 15; 48(7):518-25. PubMed ID: 9701014
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.